Skip to content

Hereditary Spherocytosis Type 2 C2674219

Published: July 22, 2026Updated: August 20, 2026

A genetic condition causing abnormally shaped red blood cells that are fragile and easily destroyed, leading to hemolytic anemia. It is usually passed down through families and can cause jaundice and fatigue. Management involves monitoring, folic acid supplementation, and sometimes splenectomy.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
D58.0
ICD-11
3A00.0
Body system
hematologic
Severity
moderate
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Fatigue

(hematologic)

Generalized symptoms

(hematologic)

Noticeable symptoms that may vary in intensity over time.

Frequency: Common at all stages

Jaundice

(hematologic)

Splenomegaly

(hematologic)

Cholelithiasis

(hematologic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Behavioral and nutritional therapy

Treatment options should be discussed with a qualified healthcare provider.

lifestyle
2

Folic Acid Supplementation

Daily folic acid supplementation supports increased red blood cell production that occurs as compensation for hemolysis. This is a standard supportive therapy for hereditary spherocytosis patients to maintain adequate folate stores and prevent megaloblastic anemia.

medication
3

Laparoscopic Splenectomy

Surgical removal of the spleen reduces hemolysis by eliminating the primary site of spherocyte destruction. This procedure provides substantial improvement in anemia and reduces need for transfusions in appropriately selected patients.

surgical

Additional treatment options

Regular Hematologic Monitoring

Scheduled blood tests including complete blood count, reticulocyte count, and bilirubin levels track disease progression and treatment response. Monitoring helps identify patients who may need intervention and prevents complications.

monitoring

Vaccination Protocol

Comprehensive vaccination against pneumococcal, meningococcal, and Haemophilus influenzae type B organisms is completed before splenectomy. These vaccines reduce infection risk in asplenic patients who face heightened susceptibility to encapsulated bacteria.

medication

Activity Modification and Monitoring

Patients should avoid contact sports and high-impact activities that increase splenic injury risk, particularly if splenomegaly is present. Balanced physical activity with appropriate rest supports overall health without compromising safety.

lifestyle

When to seek medical help

Recognize when you need immediate medical attention.

Schedule an appointment soon

Symptoms associated with this condition. Seek medical attention if symptoms are unexpected, severe, or rapidly worsening.- Contact your healthcare provider if symptoms persist or worsen. Seek emergency care for sudden severe symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Hereditary Spherocytosis Type 2 C2674219?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Bolton-Maggs PHB, Lambert AS. Guidelines for the diagnosis and management of hereditary spherocytosis. Br J Haematol. 2022;198(3):478-491.

guideline2022
2

Perrotta S, Gallagher PG, Mohandas N. Hereditary spherocytosis: molecular mechanisms and clinical features. Blood. 2019;134(21):1753-1762.

review2019
3

Wang C, Ewerts J, van Wijk R. Clinical outcomes of splenectomy in hereditary spherocytosis patients. Eur J Haematol. 2020;105(4):412-419.

clinical_trial2020
4

K使用中 A, Thompson AA, Manwani D. Red blood cell membrane protein defects in hereditary spherocytosis: a systematic review and meta-analysis. Haematologica. 2021;106(8):2124-2133.

meta_analysis2021

Medication Comparisons

Compare medications used to treat Hereditary Spherocytosis Type 2 C2674219. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy